These data are constantly confirmed by new evidence and altogether stress the utility to move to dPCR for the monitoring of MRD in CML patients, particularly in subjects presenting a low level of BCR-ABL1 transcript and potentially eligible for stopping TKI therapy. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.